Wall Street brokerages expect that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post sales of $1.48 billion for the current quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Regeneron Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.53 billion and the lowest estimate coming in at $1.41 billion. Regeneron Pharmaceuticals reported sales of $1.23 billion during the same quarter last year, which indicates a positive year over year growth rate of 20.3%. The business is expected to issue its next quarterly earnings results on Thursday, February 8th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $1.48 billion for the current year, with estimates ranging from $5.69 billion to $5.81 billion. For the next fiscal year, analysts anticipate that the business will report sales of $6.24 billion per share, with estimates ranging from $5.89 billion to $6.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period last year, the company earned $3.13 EPS.

Several research analysts recently issued reports on the company. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $450.00 to $395.00 in a research report on Friday, October 20th. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Oppenheimer reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Finally, Zacks Investment Research raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $471.11.

Regeneron Pharmaceuticals (REGN) opened at $366.96 on Monday. The stock has a market capitalization of $39,430.00, a price-to-earnings ratio of 33.33, a P/E/G ratio of 1.41 and a beta of 1.52. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a 12-month low of $340.09 and a 12-month high of $543.55.

A number of hedge funds have recently added to or reduced their stakes in REGN. Harding Loevner LP boosted its stake in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Regeneron Pharmaceuticals by 15,495.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after purchasing an additional 1,552,948 shares during the last quarter. FMR LLC boosted its stake in Regeneron Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its stake in Regeneron Pharmaceuticals by 500,446.2% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after purchasing an additional 325,290 shares during the last quarter. Finally, PointState Capital LP acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $78,199,000. Institutional investors and hedge funds own 66.63% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Quarterly Sales of $1.48 Billion” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/15/analysts-anticipate-regeneron-pharmaceuticals-inc-regn-will-post-quarterly-sales-of-1-48-billion.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.